Eliem Therapeutics (ELYM) Competitors $2.34 -0.08 (-3.31%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ELYM vs. IMMP, FDMT, CCCC, LRMR, BNTC, CMPS, FHTX, ACIU, AMLX, and LFCRShould you be buying Eliem Therapeutics stock or one of its competitors? The main competitors of Eliem Therapeutics include Immutep (IMMP), 4D Molecular Therapeutics (FDMT), C4 Therapeutics (CCCC), Larimar Therapeutics (LRMR), Benitec Biopharma (BNTC), COMPASS Pathways (CMPS), Foghorn Therapeutics (FHTX), AC Immune (ACIU), Amylyx Pharmaceuticals (AMLX), and Lifecore Biomedical (LFCR). These companies are all part of the "pharmaceutical products" industry. Eliem Therapeutics vs. Immutep 4D Molecular Therapeutics C4 Therapeutics Larimar Therapeutics Benitec Biopharma COMPASS Pathways Foghorn Therapeutics AC Immune Amylyx Pharmaceuticals Lifecore Biomedical Eliem Therapeutics (NASDAQ:ELYM) and Immutep (NASDAQ:IMMP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, community ranking, dividends, earnings and risk. Is ELYM or IMMP more profitable? Immutep's return on equity of 0.00% beat Eliem Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Eliem TherapeuticsN/A -47.03% -45.97% Immutep N/A N/A N/A Which has more volatility and risk, ELYM or IMMP? Eliem Therapeutics has a beta of -0.39, suggesting that its share price is 139% less volatile than the S&P 500. Comparatively, Immutep has a beta of 2.22, suggesting that its share price is 122% more volatile than the S&P 500. Do institutionals and insiders hold more shares of ELYM or IMMP? 69.8% of Eliem Therapeutics shares are held by institutional investors. Comparatively, 2.3% of Immutep shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by insiders. Comparatively, 3.1% of Immutep shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media prefer ELYM or IMMP? In the previous week, Immutep had 7 more articles in the media than Eliem Therapeutics. MarketBeat recorded 7 mentions for Immutep and 0 mentions for Eliem Therapeutics. Eliem Therapeutics' average media sentiment score of 1.83 beat Immutep's score of 0.36 indicating that Eliem Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Eliem Therapeutics Very Positive Immutep Neutral Do analysts rate ELYM or IMMP? Immutep has a consensus target price of $8.50, indicating a potential upside of 299.06%. Given Immutep's stronger consensus rating and higher possible upside, analysts plainly believe Immutep is more favorable than Eliem Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Immutep 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings & valuation, ELYM or IMMP? Immutep has higher revenue and earnings than Eliem Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEliem TherapeuticsN/AN/A-$35.12M-$0.53-4.42Immutep$5.14M60.28-$28.01MN/AN/A Does the MarketBeat Community believe in ELYM or IMMP? Immutep received 303 more outperform votes than Eliem Therapeutics when rated by MarketBeat users. Likewise, 72.56% of users gave Immutep an outperform vote while only 56.25% of users gave Eliem Therapeutics an outperform vote. CompanyUnderperformOutperformEliem TherapeuticsOutperform Votes956.25% Underperform Votes743.75% ImmutepOutperform Votes31272.56% Underperform Votes11827.44% SummaryImmutep beats Eliem Therapeutics on 11 of the 14 factors compared between the two stocks. Ad Banyan Hill PublishingTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just spent six months investigating this...and what I found is shocking.Click here and I’ll show you exactly how to position your money Get Eliem Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELYM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELYM vs. The Competition Export to ExcelMetricEliem TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$69.62M$6.85B$5.14B$9.31BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-4.4210.75135.1817.54Price / SalesN/A287.861,228.03140.34Price / CashN/A56.6540.6537.95Price / Book0.605.394.884.92Net Income-$35.12M$152.04M$118.97M$225.78M7 Day Performance-24.52%-4.32%15.73%-1.58%1 Month Performance-23.53%2.80%15.69%6.67%1 Year Performance-14.60%17.30%34.73%22.48% Eliem Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELYMEliem TherapeuticsN/A$2.34-3.3%N/A-11.4%$69.62MN/A-4.4220Positive NewsGap DownIMMPImmutep1.5604 of 5 stars$2.08-4.6%$8.50+308.7%-14.5%$302.56M$5.14M0.002,021News CoverageGap UpFDMT4D Molecular Therapeutics2.7235 of 5 stars$6.54+0.6%$42.13+544.1%-64.4%$302.33M$17,000.00-2.28201Short Interest ↑CCCCC4 Therapeutics1.8533 of 5 stars$4.28-2.3%$10.00+133.6%-18.2%$302.12M$33.67M-2.58150Gap DownLRMRLarimar Therapeutics1.9737 of 5 stars$4.70-23.8%$20.43+334.7%+2.4%$299.91MN/A-3.5630Analyst ForecastNews CoverageGap DownHigh Trading VolumeBNTCBenitec Biopharma3.6559 of 5 stars$12.76+8.4%$24.43+91.4%+278.9%$296.29M$80,000.000.0020Analyst ForecastShort Interest ↑CMPSCOMPASS Pathways2.9382 of 5 stars$4.30+1.9%$33.60+681.4%-47.5%$294.21MN/A-1.92120Short Interest ↓Positive NewsFHTXFoghorn Therapeutics2.9771 of 5 stars$5.27-0.6%$15.20+188.4%+4.2%$292.98M$25.52M-2.63120Analyst ForecastShort Interest ↓News CoverageGap DownHigh Trading VolumeACIUAC Immune2.6486 of 5 stars$2.93-0.7%$12.00+309.6%-25.0%$289.89M$16.48M-6.41140Positive NewsAMLXAmylyx Pharmaceuticals4.2863 of 5 stars$4.18+1.5%$7.33+75.4%-69.9%$286.53M$196.49M-1.08200Short Interest ↓News CoverageLFCRLifecore Biomedical3.6897 of 5 stars$7.73+1.6%$10.00+29.4%+27.7%$284.67M$128.44M97.50690 Related Companies and Tools Related Companies Immutep Alternatives 4D Molecular Therapeutics Alternatives C4 Therapeutics Alternatives Larimar Therapeutics Alternatives Benitec Biopharma Alternatives COMPASS Pathways Alternatives Foghorn Therapeutics Alternatives AC Immune Alternatives Amylyx Pharmaceuticals Alternatives Lifecore Biomedical Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ELYM) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eliem Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELYM Stock Alerts